“Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s18. doi:10.25251/skin.5.supp.18.